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Glioblastoma multiforme (GBM) is a malignant brain tumor that is resistant to existing drug and 
radiation-based therapies. As a result of this resistance, 90% of patients diagnosed with GBM 
succumb within two years, highlighting the urgent need for new treatment strategies. In a previous 
study, Ding, et al. (2013), reported a kinase-specific shRNA screen that identified BUB1B/BUBR1 as 
a requirement for GBM cell proliferation but not for normal cells. In the current study reported 
inGenes & Development, graduate student Christopher G. Hubert (Molecular and Cellular Biology 
Program), and Drs. Robert K. Bradley (Public Health Sciences and Basic Sciences Divisions), 
James M. Olson (Clinical Research Division), and Patrick J. Paddison (Human Biology Division), 
along with a team of collaborators, expand this approach to a genome wide shRNA study, identifying 
the spliceosome component PHF5A as a novel viability requirement for glioblastoma stem cells 
(GSCs), which may prove to be a candidate therapeutic target for GBM. 
Hubert, et al. infected GSC and normal neural stem cells (NSC) with pools of shRNA-expressing 
viruses and then assessed the cells for differences in shRNA content over time. Most of the tested 
shRNAs either caused no difference or were underrepresented in the NSCs more than the GSCs; 
however, the authors identified 27 candidate genes which preferentially inhibited GSCs. Seven of 
these candidate genes were validated by other criteria and in multiple cell lines; the strongest hit was 
PHF5A. 
Among other functions, PHF5A is a core component of the U2 snRNP spliceosome, a nucleoprotein 
complex necessary for the removal of introns from pre-mRNA after transcription.  Deep RNA 
sequencing (RNA-seq) experiments identified exon skipping or intron retention in hundreds of genes 
in PHF5A k/d GSCs but not NSCs. These aberrant splicing phenotypes correlated with a subset of 
exons encoding characteristic sequences in the 3' splice site, leading to severe RNA processing 
defects in many cell cycle progression genes. Furthermore, this phenotype was replicated with three 
different small molecule inhibitors of the U2 snRNP complex of the spliceosome or by knocking 
down known PHF5A binding partners in the spliceosome. Before PHF5A k/d caused GSC cell death, 
the authors also noticed dramatic G2/M phase cell cycle arrest. Taken together, these data suggest 
that PHF5A functions to recognize a specific class of exons with distinctive 3' splice sites which are 
critical for cell cycle progression in GSC. 
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To evaluate this altered splicing phenotype in vivo, the authors employed a competition experiment 
in a xenograft GBM model. PHF5A-shRNA expressing GSCs were unable to proliferate and engraft 
in vivo and exhibited characteristics of cell cycle arrest two days post implantation. The authors also 
established GBM tumors expressing a doxycycline-inducible PHF5A-specific shRNA diminished to 
near undetectable levels after doxycycline administration, while control shRNA transduced tumors 
grew normally. These findings confirm that PHF5A is necessary for both GBM formation and 
maintenance. Finally, normal NSCs, astrocytes, or fibroblasts immortalized or transformed with the 
oncogenes Myc or Ras became acutely sensitive to inhibitors that target the PHF5A-containing 
component of the spliceosome. This finding suggests that inhibition of PHF5A may be generalizable 
to a wide range of cancers that rely on these oncogenes. 
"PHF5A could be an incredibly powerful target in cancer therapeutics, but it is extremely difficult for 
traditional small molecule therapeutics.  It is nuclear, involves protein:protein interactions and there 
is no enzymatic "pocket" to target. …[W]e intend to embark on a very challenging project to identify 
peptide therapeutics that cross the blood brain barrier, enter the nucleus, and disrupt the pertinent 
interactions," said Dr. Jim Olson. 
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Image modified from Genes & Development 
Schematic of the shRNA screen. GSC or NSC cells 
were infected with a panel of shRNA-expressing 
viruses. Differential shRNA expression was 
determined three weeks later to identify genes 
necessary for GSC but not NSC viability. 
 
